Clean energy stocks in 2018 are on the cusp of massive growth, as the sector is projected to expand by 500% in the United States alone…
The Energy Information Agency is projecting renewable energy production to grow 500% by 2040.
The World’s First “Universal Fuel”: Physicists have known about an unlimited source of free fuel for over 100 years. See why tech companies are investing millions in this fuel (and how to join them). Click here…
And that means right now is the time to invest in clean energy stocks before they begin to soar.
To help Money Morning readers profit from the massive industry growth ahead, we’re giving our readers one of the best clean energy stocks to buy right now. More on that pick in just a bit, but we want to first show you why the renewable energy sector is set to soar…
How Renewables Will Power Clean Energy Stocks in 2018
There are three major catalysts propelling alternative energy sources to explosive growth potential. And as the sector grows, so will renewable energy stocks…
Best Clean Energy Stocks To Watch For 2019: Bloomin' Brands, Inc.(BLMN)
Advisors’ Opinion:
- [By Joseph Griffin]
BidaskClub downgraded shares of Bloomin’ Brands (NASDAQ:BLMN) from a hold rating to a sell rating in a research note issued to investors on Tuesday.
- [By Joseph Griffin]
Bloomin’ Brands (NASDAQ: BLMN) and Brinker International (NYSE:EAT) are both small-cap retail/wholesale companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, dividends, earnings, institutional ownership and analyst recommendations.
- [By Joseph Griffin]
Equities research analysts expect Bloomin’ Brands Inc (NASDAQ:BLMN) to report earnings per share of $0.08 for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Bloomin’ Brands’ earnings. The highest EPS estimate is $0.12 and the lowest is $0.05. Bloomin’ Brands reported earnings of $0.12 per share during the same quarter last year, which indicates a negative year over year growth rate of 33.3%. The business is scheduled to issue its next earnings report on Friday, November 2nd.
- [By Sean Williams]
The casual-dining restaurant stock I’d most suggest avoiding in this industry is Bloomin’ Brands (NASDAQ:BLMN), the parent of Outback Steakhouse, Carrabba’s Italian Grill, Bonefish Grill, and Fleming’s Steakhouse.
Best Clean Energy Stocks To Watch For 2019: Valspar Corporation (VAL)
Advisors’ Opinion:
- [By Max Byerly]
Valorbit (CURRENCY:VAL) traded 0% higher against the dollar during the 1 day period ending at 11:00 AM Eastern on June 9th. One Valorbit coin can currently be bought for approximately $0.0001 or 0.00000001 BTC on exchanges. Valorbit has a market cap of $537,598.00 and $0.00 worth of Valorbit was traded on exchanges in the last 24 hours. In the last seven days, Valorbit has traded up 5.8% against the dollar.
- [By Shane Hupp]
Shares of ValiRx Plc (LON:VAL) rose 5.6% during mid-day trading on Thursday . The company traded as high as GBX 1.90 ($0.02) and last traded at GBX 1.90 ($0.02). Approximately 587,748 shares were traded during trading, a decline of 85% from the average daily volume of 3,820,000 shares. The stock had previously closed at GBX 1.80 ($0.02).
- [By Stephan Byrd]
Valorbit (CURRENCY:VAL) traded up 0% against the U.S. dollar during the 1 day period ending at 0:00 AM E.T. on June 18th. One Valorbit coin can now be bought for approximately $0.0001 or 0.00000001 BTC on popular exchanges. Valorbit has a total market capitalization of $537,598.00 and $0.00 worth of Valorbit was traded on exchanges in the last day. During the last week, Valorbit has traded 5.8% higher against the U.S. dollar.
Best Clean Energy Stocks To Watch For 2019: Merrimack Pharmaceuticals, Inc.(MACK)
Advisors’ Opinion:
- [By Max Byerly]
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:
Get Merrimack Pharmaceuticals alerts:
Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod (finance.yahoo.com) Merrimack Fails Phase 2 Pancreatic Cancer Study, But Opportunity Remains (seekingalpha.com) Merrimack Pharmaceuticals’ (MACK) “Hold” Rating Reaffirmed at Robert W. Baird (americanbankingnews.com) Merrimack Crashes as Phase II Pancreatic Cancer Study Fails (zacks.com) MM-141 (benzinga.com)
Several equities analysts have commented on MACK shares. Zacks Investment Research raised Merrimack Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.50 price objective on the stock in a research report on Wednesday, April 25th. JPMorgan Chase & Co. downgraded Merrimack Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research report on Monday. Robert W. Baird cut their price objective on Merrimack Pharmaceuticals from $12.00 to $7.00 and set a “neutral” rating on the stock in a research report on Tuesday. Finally, ValuEngine raised Merrimack Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday.
- [By Chris Lange]
Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) shares were absolutely crushed on Monday after the firm gave an update from its midstage pancreatic cancer study. Specifically, the top-line results come from the CARRIE study, a randomized Phase 2 trial evaluating the addition of MM-141 (istiratumab) to standard-of-care treatment in patients with previously untreated metastatic pancreatic cancer.
- [By Lisa Levin]
Check out these big penny stock gainers and losers
Losers
Aceto Corporation (NASDAQ: ACET) fell 41.9 percent to $4.30 in pre-market trading. ACETO board disclosed that it is taking proactive steps to address business and financial challenges. Canaccord Genuity downgraded Aceto from Buy to Sell.
Helios and Matheson Analytics Inc. (NASDAQ: HMNY) fell 25.3 percent to $2.86 in pre-market trading after reporting an ATM offering of $150 million.
Pier 1 Imports, Inc. (NYSE: PIR) fell 17.4 percent to $2.86 in pre-market trading after reporting a fourth quarter sales miss. Comps were down 7.5 percent in the quarter.
Sleep Number Corporation (NASDAQ: SNBR) fell 12.4 percent to $32.00 in pre-market trading following a first quarter earnings miss.
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) fell 10.2 percent to $11.90 in pre-market trading on news of $125 million convertible debt offering.
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares fell 8 percent to $8.02 in pre-market trading after dropping 2.02 percent on Wednesday.
Exponent, Inc. (NASDAQ: EXPO) shares fell 5.6 percent to $80 in pre-market trading.
Lumentum Holdings Inc. (NASDAQ: LITE) shares fell 4.8 percent to $60.00 in pre-market trading after rising 1.78 percent on Wednesday.
vTv Therapeutics Inc. (NASDAQ: VTVT) fell 4.6 percent to $2.10 in pre-market trading after surging 84.87 percent on Wednesday.
Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) shares fell 4.5 percent to $40.07 in pre-market trading after the company reported Q1 results.
Align Technology, Inc.. (NASDAQ: ALGN) fell 3.5 percent to $267.40 in pre-market trading after rising 1.61 percent on Wednesday.
Transocean Ltd. (NYSE: RIG) shares fell 3.5 percent to $12 in pre-market trading after the company issued quarterly fleet status report.
GoPro, Inc. (NASDAQ: GPRO) fell 3.2 percent to $4.90 in pre-market trading.
Unilever PLC (NYSE: UL) fell 2.6 percent to $54.73 in pre-market
Best Clean Energy Stocks To Watch For 2019: Timken Company (TKR)
Advisors’ Opinion:
- [By Max Byerly]
ValuEngine downgraded shares of Timken (NYSE:TKR) from a sell rating to a strong sell rating in a research report sent to investors on Monday.
A number of other research firms have also recently commented on TKR. Bank of America increased their target price on Timken from $50.00 to $51.00 and gave the company an underperform rating in a research note on Tuesday, May 22nd. Stifel Nicolaus upgraded shares of Timken from a hold rating to a buy rating and upped their price target for the company from $52.00 to $60.00 in a research report on Monday, May 28th. Zacks Investment Research lowered shares of Timken from a buy rating to a hold rating in a research report on Wednesday, March 21st. Vertical Research upgraded shares of Timken from a hold rating to a buy rating in a research report on Friday, May 4th. Finally, CL King began coverage on shares of Timken in a research report on Thursday, June 28th. They set a neutral rating for the company. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. Timken currently has a consensus rating of Hold and an average target price of $52.83.
- [By Max Byerly]
Get a free copy of the Zacks research report on Timken (TKR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Shane Hupp]
CryptoInsight (CURRENCY:TKR) traded flat against the dollar during the 24 hour period ending at 21:00 PM Eastern on September 11th. One CryptoInsight token can now be purchased for about $0.0040 or 0.00000063 BTC on major exchanges including HitBTC and IDEX. Over the last week, CryptoInsight has traded down 15.8% against the dollar. CryptoInsight has a market cap of $49,784.00 and $0.00 worth of CryptoInsight was traded on exchanges in the last 24 hours.
- [By Logan Wallace]
Bank of Montreal Can acquired a new position in shares of Timken Co (NYSE:TKR) during the second quarter, HoldingsChannel reports. The firm acquired 2,822 shares of the industrial products company’s stock, valued at approximately $123,000.
- [By Max Byerly]
Get a free copy of the Zacks research report on Timken (TKR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
